Researchers discover key driver of atopic dermatitis

January 17, 2018, La Jolla Institute for Allergy and Immunology
Periostin (shown in pink) is being used in the clinic as a marker for allergic diseases such as asthma as well as atopic dermatitis. Left image: Periostin is overexpressed in atopic dermatitis. Right image: Blocking LIGHT also blocks periostin expression. Credit: Dr. Rana Herro, La Jolla Institute for Allergy and Immunology

Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes skin inflammation in atopic dermatitis and the characteristic thickening of the skin.

Their work, published in the January 16, 2018, online edition of the Journal of Experimental Medicine, demonstrates that LIGHT, a member of the (TNF) super family, directly controls the hyperproliferation of keratinocytes as well as the expression of periostin, a protein that contributes to the clinical features of atopic dermatitis as well as other such as scleroderma.

"Periostin is being used in the clinic as a marker for allergic diseases such as asthma as well as atopic dermatitis," explains senior author Michael Croft, Ph.D., professor and head in the Division of Immune Regulation. "The fact that LIGHT acts upstream of periostin and is controlling its production really reinforces the idea that this is potentially a very good clinical target for treatment of atopic dermatitis and other inflammatory skin diseases."

In fact, a therapeutic antibody that neutralizes the activity of LIGHT successfully suppressed after they first appeared, suggesting that therapies based on blocking LIGHT may add a valuable treatment option for patients suffering from severe eczema, an often debilitating disease.

LIGHT is a cytokine primarily produced by T cells and exerts its function through two receptors, HVEM and LTβR. In an earlier study, Rana Herro, Ph.D., an instructor in the Croft lab and lead author on both studies, had shown that LIGHT plays a key role in skin inflammation in scleroderma, an autoimmune disease that results in the overproduction of collagen leading to the thickening and scarring of tissue. But whether LIGHT signaling is also involved in other types of skin inflammation was unknown.

To find out whether LIGHT contributes to skin inflammation in atopic dermatitis, Herro used an experimental model for atopic dermatitis that replicates the human disease. Her experiments revealed that LIGHT-deficient mice only displayed minimal clinical symptoms compared to normal control mice. The same was true for animals that only lacked the LIGHT-receptor HVEM in keratinocytes, the predominant cell type in the outermost layer of the skin. "This is the important part of the study," says Herro. "Specifically deleting the receptor in keratinocytes was enough to abrogate disease."

A closer look revealed that LIGHT stimulates the proliferation of keratinoyctes and thus the structural remodeling of the skin. It also showed that LIGHT strongly induces the expression of periostin. This protein is highly expressed in the skin of patients with dermatitis and scleroderma, and animal studies have found it is essential for , although exactly how it functions is still being debated.

"We knew that LIGHT acts as a pro-inflammatory molecule on immune cells but we were able to implicate, for the first time in a disease setting, that this molecule acts on non-immune cells like the structural cells of the skin," says Herro. "LIGHT directly drives fibrosis, a structural remodeling process that leads to the thickening and hardening of the ."

The researchers then went back and used an existing therapeutic antibody to block the interaction of LIGHT with its receptor, HVEM, after disease had already manifested. The antibody treatment suppressed inflammation and strongly reduced epidermal thickening. "That's great news for patients suffering from eczema," says Herro. "Our findings suggest that therapies that block LIGHT signaling might halt in humans and maybe even reverse symptoms."

Explore further: Researchers reveal potential target for the treatment of skin inflammation in eczema and psoriasis

More information: Rana Herro et al, LIGHT–HVEM signaling in keratinocytes controls development of dermatitis, The Journal of Experimental Medicine (2018). DOI: 10.1084/jem.20170536

Related Stories

Researchers reveal potential target for the treatment of skin inflammation in eczema and psoriasis

May 22, 2017
Superficially, psoriasis and atopic dermatitis may appear similar but their commonalities are only skin deep. Atopic dermatitis, also known as eczema, is primarily driven by an allergic reaction, while psoriasis is considered ...

How the skin becomes inflamed

November 8, 2017
Publishing online this week in Cell Host & Microbe, researchers at Johns Hopkins report the discovery of a key underlying immune mechanism that explains why to how our skin becomes inflamed from conditions such as atopic ...

Countering atopic dermatitis immune reactions

August 4, 2017
Human leukocyte antigen (HLA)-G is a protein that interacts with specific cell receptors to inhibit immune responses. The protein is best known for its role in protecting the fetus from attack by its mother's immune system. ...

New Atopic Dermatitis Yardstick provides practical guidance and management insights

January 4, 2018
Patients with atopic dermatitis (AD) - also known as eczema - often face a tough, uphill battle for treatment. Symptoms include severe itching, scaly rashes, extreme dry skin and inflammation. Those who suffer from AD spend ...

Why air pollutants make some people vulnerable to atopic dermatitis

November 23, 2016
Tohoku University Graduate School of Medicine and Tohoku Medical Megabank Organization (ToMMo) are pleased to announce the published results of a study into why air pollutants cause some people to be more susceptible to atopic ...

Scientists identify single-gene mutations that lead to atopic dermatitis

June 19, 2017
Researchers have identified mutations in a gene called CARD11 that lead to atopic dermatitis, or eczema, an allergic skin disease. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of ...

Recommended for you

Researchers identify source of molecule linked to nasal polyps, asthma attacks

May 23, 2018
A new discovery about how the immune system responds to common sinus infections and asthma could explain why patients develop these issues in the first place and ultimately may lead to improved targeted therapies. Researchers ...

Study demonstrates new treatment for severe asthma

May 22, 2018
Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat ...

Eczema drug effective against severe asthma

May 21, 2018
Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe better than standard therapies. Dupilumab, an injectable ...

Neuron guidance factor found to play a key role in immune cell function

May 21, 2018
Macrophages are white blood cells involved in a variety of biological functions, from destroying infectious pathogens to repairing damaged tissue. To carry out their different roles, macrophages must first be activated and ...

Immune cells hold promise in slowing down ALS

May 21, 2018
Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this relentlessly progressive ...

First clues to the causes of multiple sclerosis

May 16, 2018
Multiple sclerosis, which affects one in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.